middle.news
Argent BioPharma Licenses CannEpil® Globally for US$5.5M Upfront and 15% Royalties
9:23am on Tuesday 7th of July, 2026 AEST
•
Healthcare
Read Story
Argent BioPharma Licenses CannEpil® Globally for US$5.5M Upfront and 15% Royalties
9:23am on Tuesday 7th of July, 2026 AEST
Key Points
US$5.5 million upfront via debt forgiveness
15% royalty on future global CannEpil® sales
Argent retains full IP ownership and manufacturing rights
Deal removes secured debt and strengthens balance sheet
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argent Biopharma (ASX:RGT)
OPEN ARTICLE